Mechanism of dimer selectivity and binding cooperativity of BRAF inhibitors
- Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, United States
- Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration, United States
- Department of Biochemistry, Department of Medicine, Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, United States
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, United States
Figures
Figure 1 with 3 supplements
The X-ray structure of the BRAFV600E dimer in complex with PHI1.
Left. Cartoon representation of the BRAFV600E dimer in complex with PHI1 (PDB: 6P7G Cotto-Rios et al., 2020, two protomers are colored tan and grey). The αC-helix, a-loop, and c-loop are colored …
Figure 1—figure supplement 1
Visualization of the H510-H477-D595 interactions at the dimer interface of BRAFV600E.
Left. Visualization of the BRAFV600E dimer (PDB ID: 6 P7G) (Cotto-Rios et al., 2020). The αC helix is colored brown and PHI1 is colored cyan. The dimer interface residues H477, H510, and D595 are …
Figure 1—figure supplement 2
Protonation and tautomer states of the interface histidines determined by the all-atom PME-CpHMD titration.
Left. Calculated probabilities of the neutral (HID in blue, HIE in orange) and charged (HIP in green) states for H477 (left) and H510 (right) at pH 7.5. The probabilities of protonation states for …
Figure 1—figure supplement 3
Convergence of the protonation/tautomer states of H477 and H510 at pH 7.5.
Running average probability of each protonation/tautomer state for H477 and H510 at pH 7.5 as a function of simulation time (top plots for protomer A and bottom plots for protomer B). Convergence of …
Figure 2 with 1 supplement
Protein-ligand interaction fingerprints for PHI1, LY3009120, Vermurafenib, and the inhibition of ERK1/2 phosphorylation in melanoma cells.
a) Left. Visualization of the back pockets (BPs) in BRAFV600E in complex with PHI1. BP-I, BP-II, and BP-III are colored blue, orange, and green, respectively. BP definitions of Liao, 2007) are …
Figure 2—figure supplement 1
Chemical structures of the monomer-selective, equipotent, and dimer-selective BRAFV600E inhibitors in Supplementary file 1A.
The chemical group responsible for forming the hydrogen bonds with E501 and/or D594 are circled in red.
Figure 3 with 5 supplements
Dimerization and inhibitor binding modulate the conformation and dynamics of the αC-helix and DFG motif of BRAFV600E.
(a–f) Probability distribution of the αC position, probability of the Lys483–Glu501 salt bridge, and probability distribution of the DFG pseudo dihedral angle in the apo monomer (blue), apo dimer …
Figure 3—figure supplement 1
Time series of αC-helix position and DFG dihedral for all apo simulations.
Time series plots of the αC-helix position (left column) and DFG dihedral (right column) for each apo protomer simulated. Each of the three replicas are represented as a separate line; for …
Figure 3—figure supplement 2
Time series of αC-helix position and DFG dihedral for all holo simulations.
Time series plots of the αC-helix position (left column) and DFG dihedral (right column) for each holo protomer simulated. Each of the three replicas are represented as a separate line; for …
Figure 3—figure supplement 3
Time series of E501-ligand hydrogen bonding.
Time series of the minimum distance between E501 carboxylate oxygens and the proton donor of LY (N5 or N6) and PHI1 (N4). Each of the three replicas are represented as a separate line; for …
Figure 3—figure supplement 4
Time series of αC-helix position.
Time series of the αC-helix position for inhibited monomer and dimer simulations. Each of the three replicas are represented as a separate line; for simplicity, a stride of 10 ns was used while …
Figure 3—figure supplement 5
RMSD time series for the monomer simulations.
Time series plots of the root-mean-square deviation (RMSD) of the protomer in each monomer simulation. The RMSD was calculated using heavy atoms of the protomer backbone, excluding residues on the …
Figure 4
Both PHI1 and LY stabilize the interprotomer contacts of BRAFV600E.
Left. The N-lobe (blue for A; grey for B) and C-lobe (red for A; orange for B) of each protomer in the BRAFV600E dimer are separated into different communities according to the difference contact …
Figure 5 with 2 supplements
Conformation of the αC helix and DFG motif is dependent on the presence or absence of PHI1 in the second protomer.
(a) The αC helix position, probability of the Glu501–Lys483 salt bridge, and DFG pseudo dihedral of the apo protomer in the one PHI1- (blue) or one LY-bound (orange) mixed dimer simulations. As a …
Figure 5—figure supplement 1
Time series of αC-helix position and DFG dihedral for all mixed simulations.
Time series plots of the αC-helix position (left column) and DFG dihedral (right column) for each protomer simulated in the mixed simulations. Each of the three replicas are represented as a …
Figure 5—figure supplement 2
RMSD time series for the dimer simulations.
Time series plots of the RMSD of the protomer in each dimer simulation. The RMSD was calculated using heavy atoms of the protomer backbone, excluding residues on the a-loop and C-helix. Each of …
Figure 6
A working model that explains dimer selectivity and binding cooperativity of BRAFV600E inhibitors.
Top left. In the monomeric BRAFV600E, the αC-helix (orange) is very flexible and exclusively samples the out states. Top right. Upon dimerization, the αC-helix is restrained and shifts inward, while …
Tables
Table 1
Summary of the fixed-protonation-state MD simulations (aggregate time of 135 μs).
| No. | System | Simulation time | Starting structure |
|---|---|---|---|
| 1 | Apo monomer | 3x5μs | 6P7G(A) |
| 2 | Apo dimer | 3x5μs | 6P7G (inhibitors removed) |
| 3 | Holo monomer:PHI1 | 6x5μs | 6P7G (A:PHI1 or B:PHI1) |
| 4 | Holo monomer:LY | 3x5μs | 5C9C (A:LY) |
| 5 | Mixed dimer:PHI1 | 3x5μs | 6P7G (apo A; B:PHI1) |
| 6 | Holo dimer:2PHI1 | 3x5μs | 6P7G (A:PHI1, B:PHI1) |
| 7 | Mixed dimer:LY | 3x5μs | 5C9C (A:LY; apo B) |
| 8 | Holo dimer:2LY | 3x5μs | 5C9C (A:LY; B:LY) |
Additional files
-
MDAR checklist
- https://cdn.elifesciences.org/articles/95334/elife-95334-mdarchecklist1-v1.pdf
-
Supplementary file 1
Supplemental tables.
Table A . List of the BRAFV600E inhibitors and the structure features of the co-crystal structures in the PDB. The monomer and dimer selectivities of inhibitors in black are based on the experimental data in Adamopoulos et al., 2021 and Cotto-Rios et al., 2020 (PHI1). The monomer and dimer selectivities of inhibitors in red were predicted by us and supported by experiments in Karoulia et al., 2017 (GDC0879) and Tkacik et al., 2023 (Tovorafenib). Note, the PDB entries indicated by an astrisk are co-crystal structures in complex with the wild type BRAF (the BRAFV600E forms are unavailable). All structures contain an inhibitor in each protomer, with the exception of PLX7904; in the PDB entry 4XV1, PLX7904 is only present in protomer A. The C helix position (in Å) is defined in the main text. Two values refer to the two protomers. The back pockets (BPs) occupied was calculated by KLIFS (Kooistra et al., 2016) based on the definition of Liao, 2007. K-E refers to the distance (in Å) between the amine nitrogen of Lys483 and the nearest carboxylate oxygen of Glu501. Table B: Average value and standard deviation of reported quantities from out dimeric BRAF simulations, separated by system and protomer. Each quantity was calculated for each replica after removing the first 2 s for equilibration.
- https://cdn.elifesciences.org/articles/95334/elife-95334-supp1-v1.docx
